Germany Brain Cancer Therapeutics Market

Germany Brain Cancer Therapeutics Market Executive Summary

Germany Brain Cancer Therapeutics Market valued at $84 Mn in 2022, projected to reach $165 Mn by 2030 with a 9.8% CAGR.

The abnormal proliferation of brain cells serves as an indication of brain cancer, where these cells exhibit characteristics that can be either malignant (cancerous) or benign (non-cancerous). While the exact cause of brain cancer remains unclear, identified risk factors include exposure to ionizing radiation and a family history of brain tumors. Common symptoms associated with a brain tumor include headaches, gradual sensory decline, issues with balance, speech impediments, and hearing difficulties. The manifestation of these symptoms varies depending on factors such as the tumor’s size, location, and growth rate. Treatment approaches for brain cancer are determined by the tumor’s type, location, and size, with frequently utilized methods including radiosurgery, chemotherapy, radiotherapy, surgery, and the use of carmustine implants.

With 8,600 new cases of brain tumors diagnosed in Germany each year, the country has a 70.9% prevalence of brain cancer. In Germany, there was an apparent rise in the frequency of brain tumors up until roughly 2005. But by 2023, the incidence rates had leveled out and were about the same as those in the Nordic nations. In Germany, brain tumors accounted for 1.4% of all newly diagnosed cancer cases in 2023. It is noteworthy that the incidence rate of brain tumors is higher in men (5.1 per 100,000) than in women (3.6 per 100,000). Meningiomas, pituitary tumors, and gliomas, including glioblastoma multiforme, are the most common kinds of brain tumors in Germany.

CureVac AG, a biopharmaceutical company, is at the forefront of developing mRNA-based immunotherapy candidates for glioblastoma treatment. Their candidate, CVM-424, is dedicated to mRNA-based immunotherapy targeting EGFRvIII, a prevalent mutation in glioblastoma. Having entered Phase I clinical trials in December 2023, the initial data for CVM-424 is expected to be available in late 2024. Additionally, CureVac's pipeline includes CV9201, another mRNA candidate currently undergoing preclinical development. This therapy is intricately designed to target multiple glioma-associated antigens, exemplifying the company's dedication to addressing the complexities of glioblastoma treatment.

Market Dynamics

Market Growth Drivers

Increasing Incidence of Brain Cancer: The age-adjusted incidence rate of brain cancer in Germany stands at approximately 430 cases per 100,000 population, and there is an anticipated increase in this figure attributed to a growing elderly population. With the extension of life expectancy, the likelihood of developing cancer, including brain cancer, is on the rise.

Rising Demand for Personalized Medicine: A growing understanding of cancer genomes and tumor variety is fuelling interest in personalized medicine and providing the way to more specialized treatment approaches. With this strategy, specific mutations or pathways within patients' malignancies can be precisely targeted, potentially improving treatment outcomes. One of the main factors driving market expansion in Germany is the country's aggressive investment in customized medicine research and its application to clinical settings.

Increasing Awareness and Advocacy: Public awareness of brain cancer is on the rise, thanks to media campaigns and advocacy initiatives. This heightened awareness contributes to early detection and a growing demand for diverse treatment options. Advocacy groups are actively striving to enhance treatment accessibility and tackle issues impacting both patients and their families.

Market Restraints

Regulatory Hurdles: Stringent regulatory requirements and approval processes can pose challenges for the development and introduction of new brain cancer treatment drugs, potentially delaying their entry into the market.

High Development Costs: The research and development costs associated with creating effective brain cancer treatment drugs can be substantial. Companies may face financial constraints in funding extensive clinical trials and obtaining necessary approvals.

Limited Efficacy of Current Treatments: The efficacy of existing brain cancer treatments may be limited, and there could be a need for breakthrough innovations to significantly improve patient outcomes. This limitation may impact the market potential for current drugs.

Healthcare Policies and Regulatory Landscape

In Germany, healthcare policies and regulatory oversight for treatment drugs are primarily governed by the Federal Institute for Drugs and Medical Devices (BfArM) and the Paul-Ehrlich-Institute (PEI). BfArM, a federal agency within the Ministry of Health, is responsible for evaluating and approving drugs for the German market, ensuring their safety, efficacy, and quality. The PEI, another regulatory authority, focuses on advanced therapies and vaccines. The country adheres to the European Medicines Agency (EMA) regulations, contributing to a harmonized approach within the European Union. The Institute for Quality and Efficiency in Health Care (IQWiG) assesses the effectiveness and cost-effectiveness of pharmaceuticals. The healthcare policies in Germany aim to balance access to innovative treatments with cost containment, fostering a robust regulatory framework to safeguard public health while promoting medical advancements.

Competitive Landscape

Key Players

• Roche
• Merck & Co.
• Bristol Myers Squibb
• Novartis
• Pfizer
• AstraZeneca
• Eli Lilly
• Sanofi
• Takeda Pharmaceutical
• AbbVie